Genmab As Stock Total Debt
| GMAB Stock | USD 21.83 0.28 1.27% |
Genmab AS fundamentals help investors to digest information that contributes to Genmab AS's financial success or failures. It also enables traders to predict the movement of Genmab Stock. The fundamental analysis module provides a way to measure Genmab AS's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genmab AS stock.
The current year's Total Debt To Capitalization is expected to grow to 0.09. Genmab | Total Debt |
Genmab AS Company Total Debt Analysis
Genmab AS's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Genmab AS Total Debt | 770 M |
Most of Genmab AS's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genmab AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Genmab Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Genmab AS is extremely important. It helps to project a fair market value of Genmab Stock properly, considering its historical fundamentals such as Total Debt. Since Genmab AS's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Genmab AS's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Genmab AS's interrelated accounts and indicators.
Click cells to compare fundamentals
Genmab Total Debt Historical Pattern
Today, most investors in Genmab AS Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Genmab AS's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Genmab AS total debt as a starting point in their analysis.
Genmab AS Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Genmab Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, Genmab AS has a Total Debt of 770 M. This is 72.01% lower than that of the Biotechnology sector and 137.08% higher than that of the Health Care industry. The total debt for all United States stocks is 85.52% higher than that of the company.
Genmab Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genmab AS's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Genmab AS could also be used in its relative valuation, which is a method of valuing Genmab AS by comparing valuation metrics of similar companies.Genmab AS is currently under evaluation in total debt category among its peers.
Genmab AS ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Genmab AS's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Genmab AS's managers, analysts, and investors.Environmental | Governance | Social |
Genmab AS Institutional Holders
Institutional Holdings refers to the ownership stake in Genmab AS that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Genmab AS's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Genmab AS's value.| Shares | Envestnet Asset Management Inc | 2024-09-30 | 1 M | Goldman Sachs Group Inc | 2024-09-30 | 825.1 K | Royal Bank Of Canada | 2024-09-30 | 797.8 K | Two Sigma Investments Llc | 2024-09-30 | 767.9 K | Wells Fargo & Co | 2024-09-30 | 700.4 K | Two Sigma Advisers, Llc | 2024-09-30 | 615.1 K | Ddd Partners, Llc | 2024-09-30 | 583.1 K | Millennium Management Llc | 2024-09-30 | 564.8 K | Voloridge Investment Management, Llc | 2024-09-30 | 548.4 K | Alliancebernstein L.p. | 2024-09-30 | 15.1 M | Blackrock Inc | 2024-06-30 | 5.1 M |
Genmab Fundamentals
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.24 % | ||||
| Operating Margin | 0.38 % | ||||
| Current Valuation | 11.74 B | ||||
| Shares Outstanding | 635.24 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 8.41 % | ||||
| Number Of Shares Shorted | 2.28 M | ||||
| Price To Earning | 66.53 X | ||||
| Price To Book | 3.11 X | ||||
| Price To Sales | 0.70 X | ||||
| Revenue | 16.47 B | ||||
| Gross Profit | 14.6 B | ||||
| EBITDA | 5.56 B | ||||
| Net Income | 5.64 B | ||||
| Cash And Equivalents | 21.61 B | ||||
| Cash Per Share | 33.05 X | ||||
| Total Debt | 770 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 13.11 X | ||||
| Book Value Per Share | 502.60 X | ||||
| Cash Flow From Operations | 7.38 B | ||||
| Short Ratio | 1.39 X | ||||
| Earnings Per Share | 1.02 X | ||||
| Price To Earnings To Growth | 0.76 X | ||||
| Target Price | 36.56 | ||||
| Number Of Employees | 2.63 K | ||||
| Beta | 0.86 | ||||
| Market Capitalization | 13.87 B | ||||
| Total Asset | 35.29 B | ||||
| Retained Earnings | 19.02 B | ||||
| Working Capital | 30.66 B | ||||
| Current Asset | 12.65 B | ||||
| Current Liabilities | 823.51 M | ||||
| Net Asset | 35.29 B |
About Genmab AS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Genmab AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genmab AS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genmab AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out Genmab AS Piotroski F Score and Genmab AS Altman Z Score analysis. For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. If investors know Genmab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genmab AS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.38) | Earnings Share 1.02 | Revenue Per Share 30.6997 | Quarterly Revenue Growth 0.176 | Return On Assets 0.1095 |
The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.